Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AXCELLA HEALTH INC.

(AXLA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Axcella Health : Goldman Sachs Downgrades Axcella Health to Neutral Rating From Buy, Adjusts Price Target to $5 From $9

09/22/2021 | 08:38am EST


ę MT Newswires 2021
All news about AXCELLA HEALTH INC.
11/18Axcella Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference
BU
11/16Chardan Research Lifts Axcella Health's Price Target to $12 From $10; Buy Rating Kept
MT
11/10AXCELLA HEALTH INC. Management's Discussion and Analysis of Financial Condition and Re..
AQ
11/10Axcella Therapeutics Reports Third Quarter Financial Results and Provides Update on Lon..
PU
11/10AXCELLA HEALTH INC. : Results of Operations and Financial Condition (form 8-K)
AQ
11/10Axcella Health Inc. Reports Earnings Results for the Third Quarter and Nine Months Ende..
CI
11/10Axcella Therapeutics Reports Third Quarter Financial Results and Provides Update on Lon..
BU
11/10Earnings Flash (AXLA) AXCELLA THERAPEUTICS Posts Q3 Loss $-0.41
MT
11/10Axcella Therapeutics Announces That Laurent Chardonnet to Depart as Chief Financial Off..
CI
11/02Axcella Therapeutics Announces Upcoming Presentations at AASLD's The Liver Meeting« 202..
BU
More news
Analyst Recommendations on AXCELLA HEALTH INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -64,2 M - -
Net cash 2021 23,6 M - -
P/E ratio 2021 -1,53x
Yield 2021 -
Capitalization 98,9 M 98,9 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 59
Free-Float 80,2%
Chart AXCELLA HEALTH INC.
Duration : Period :
Axcella Health Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AXCELLA HEALTH INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 2,57 $
Average target price 14,38 $
Spread / Average Target 459%
EPS Revisions
Managers and Directors
William R. Hinshaw President, Chief Executive Officer & Director
Laurent Chardonnet Chief Financial Officer & Senior Vice President
David R. Epstein Chairman
Tony Tramontin Chief Scientific Officer, Senior VP-R&D
Alison Schecter President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
AXCELLA HEALTH INC.-50.48%99
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.23%66 409
WUXI APPTEC CO., LTD.26.31%65 758
VERTEX PHARMACEUTICALS-13.76%51 819